BMY vs. MRK

Last updated Apr 1, 2026

Compare and contrast key facts about Bristol-Myers Squibb Company (BMY) and Merck & Co., Inc. (MRK).

Performance

BMY vs. MRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bristol-Myers Squibb Company (BMY) and Merck & Co., Inc. (MRK). The values are adjusted to include any dividend payments, if applicable.

BMY vs. MRK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BMY Bristol-Myers Squibb Company	13.77%	0.11%	15.81%	-26.14%	18.98%	2.88%	0.41%	27.74%	-12.90%	7.71%
MRK Merck & Co., Inc.	15.13%	9.79%	-6.26%	1.01%	49.42%	1.75%	-7.20%	22.27%	39.95%	-1.49%

Fundamentals

Market Cap BMY : $123.79B MRK : $299.28B
EPS BMY : $3.46 MRK : $7.30
PE Ratio BMY : 17.53 MRK : 16.47
PEG Ratio BMY : 1.00 MRK : 0.01
PS Ratio BMY : 2.57 MRK : 4.63
PB Ratio BMY : 2.22 MRK : 5.77
Total Revenue (TTM) BMY : $48.19B MRK : $65.01B
Gross Profit (TTM) BMY : $30.43B MRK : $52.98B
EBITDA (TTM) BMY : $13.82B MRK : $28.80B

Returns By Period

In the year-to-date period, BMY achieves a 13.77% return, which is significantly lower than MRK's 15.13% return. Over the past 10 years, BMY has underperformed MRK with an annualized return of 2.72%, while MRK has yielded a comparatively higher 12.31% annualized return.

BMY

• 1D: 1.54%
• 1M: -2.76%
• YTD: 13.77%
• 6M: 37.94%
• 1Y: 4.47%
• 3Y*: 0.11%
• 5Y*: 3.12%
• 10Y*: 2.72%

MRK

• 1D: 1.85%
• 1M: -2.13%
• YTD: 15.13%
• 6M: 45.62%
• 1Y: 38.88%
• 3Y*: 7.42%
• 5Y*: 13.86%
• 10Y*: 12.31%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BMY vs. MRK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BMY

BMY Risk / Return Rank: 45
BMY Sharpe Ratio Rank: 48
BMY Sortino Ratio Rank: 41
BMY Omega Ratio Rank: 40
BMY Calmar Ratio Rank: 48
BMY Martin Ratio Rank: 47

MRK

MRK Risk / Return Rank: 79
MRK Sharpe Ratio Rank: 82
MRK Sortino Ratio Rank: 78
MRK Omega Ratio Rank: 76
MRK Calmar Ratio Rank: 80
MRK Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BMY vs. MRK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BMY	MRK	Difference
Sharpe ratio Return per unit of total volatility	0.16	1.34	-1.19
Sortino ratio Return per unit of downside risk	0.43	1.96	-1.53
Omega ratio Gain probability vs. loss probability	1.05	1.25	-0.20
Calmar ratio Return relative to maximum drawdown	0.22	2.19	-1.96
Martin ratio Return relative to average drawdown	0.35	5.34	-4.99
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BMY vs. MRK - Sharpe Ratio Comparison

The current BMY Sharpe Ratio is 0.16, which is lower than the MRK Sharpe Ratio of 1.34. The chart below compares the historical Sharpe Ratios of BMY and MRK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BMY	MRK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.16	1.34	-1.19
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.13	0.60	-0.47
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.11	0.54	-0.44
Sharpe Ratio (All Time) Calculated using the full available price history	0.35	0.49	-0.13

Correlation

The correlation between BMY and MRK is 0.51, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

BMY vs. MRK - Dividend Comparison

BMY's dividend yield for the trailing twelve months is around 4.11%, more than MRK's 2.76% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BMY Bristol-Myers Squibb Company	4.11%	4.60%	4.24%	4.44%	3.00%	2.36%	3.69%	2.55%	3.08%	2.55%	1.95%	2.17%
MRK Merck & Co., Inc.	2.76%	3.12%	3.14%	2.72%	2.52%	3.41%	3.03%	2.48%	2.60%	3.36%	3.14%	3.43%

Drawdowns

BMY vs. MRK - Drawdown Comparison

The maximum BMY drawdown since its inception was -72.03%, roughly equal to the maximum MRK drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for BMY and MRK.

Drawdown Indicators

	BMY	MRK	Difference
Max Drawdown Largest peak-to-trough decline	-72.03%	-68.61%	-3.42%
Max Drawdown (1Y) Largest decline over 1 year	-25.79%	-15.67%	-10.12%
Max Drawdown (5Y) Largest decline over 5 years	-47.67%	-43.44%	-4.23%
Max Drawdown (10Y) Largest decline over 10 years	-47.67%	-43.44%	-4.23%
Current Drawdown Current decline from peak	-13.61%	-4.04%	-9.57%
Average Drawdown Average peak-to-trough decline	-22.40%	-18.89%	-3.51%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.63%	7.44%	+10.19%

Volatility

BMY vs. MRK - Volatility Comparison

Bristol-Myers Squibb Company (BMY) has a higher volatility of 6.67% compared to Merck & Co., Inc. (MRK) at 5.85%. This indicates that BMY's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BMY	MRK	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.67%	5.85%	+0.82%
Volatility (6M) Calculated over the trailing 6-month period	19.42%	19.79%	-0.37%
Volatility (1Y) Calculated over the trailing 1-year period	28.60%	29.08%	-0.48%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	23.66%	23.30%	+0.36%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.08%	22.68%	+2.40%

Financials

BMY vs. MRK - Profitability Comparison

The chart below illustrates the profitability comparison between Bristol-Myers Squibb Company and Merck & Co., Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.

MRK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a gross profit of 15.20B and revenue of 16.40B. Therefore, the gross margin over that period was 92.7%.

BMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.

MRK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported an operating income of 8.74B and revenue of 16.40B, resulting in an operating margin of 53.3%.

BMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.

MRK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a net income of 2.96B and revenue of 16.40B, resulting in a net margin of 18.1%.